Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:46:00 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - http://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.13.43·4.210.13.80-0.07-1.82,732.29,59110,6403.88  3.95  3.748.83  1.6317:42:47Apr 2215 min RT 2¢

Recent Trades - Last 10 of 10640
Time ETExPriceChangeVolume
17:42:47Q3.880.0110
16:13:43Q3.80-0.0731
16:11:18Q3.880.0120
16:05:20Q3.74-0.131
16:00:03Q3.78-0.094,265
16:00:02Q3.80-0.07800
16:00:02Q3.80-0.07700
16:00:02Q3.80-0.0713
16:00:02Q3.80-0.073,700
16:00:02Q3.80-0.072,900

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 16:30U:FATENews ReleaseFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
2024-04-03 08:00U:FATENews ReleaseFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 08:45U:FATENews ReleaseFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
2024-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming March Investor Conferences
2024-02-26 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-15 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
2024-02-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:00U:FATENews ReleaseFate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
2023-12-13 17:00U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:01U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
2023-10-25 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
2023-08-31 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming September Investor Conferences
2023-08-08 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
2023-07-28 08:00U:FATENews ReleaseFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
2023-05-31 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming June Investor Conferences
2023-05-03 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates